Nanotherapeutics Overcoming the Blood-Brain Barrier for Glioblastoma Treatment

• Autori principali: Lin Tang (Autore), Yicheng Feng (Autore), Sai Gao (Autore), Qingchun Mu (Autore), Chaoyong Liu (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Glioblastoma (GBM) is the most common malignant primary brain tumor with a poor prognosis. The current standard treatment regimen represented by temozolomide/radiotherapy has an average survival time of 14.6 months, while the 5-year survival rate is still less than 5%. New therapeutics are still hig...